source
- ArriVent BioPharma's Phase 3 lung cancer trial misses primary endpoint, shares tumbleArriVent BioPharma reported that its investigational EGFR tyrosine kinase inhibitor firmonertinib did not achieve a statistically significant improvement in progression-free survival in the Phase 3…
- Cadrenal Therapeutics launches strategic review to explore sale or partnership for its late-stage cardiology pipelineCadrenal Therapeutics, a heart-focused biotech, announced a strategic review of its late-stage cardiology pipeline, seeking to offload assets or the entire company. The board is evaluating options…